Cardiovascular outcomes trials in type 2 diabetes: Where Do We Go From Here? Ref lections From a Diabetes Care Editors' Expert Forum

Diabetes Care

Volumn 41, Issue 1, 2018, Pages 14-31

  Cefalu, William T ^a   Kaul, Sanjay ^b   Gerstein, Hertzel C ^c   Holman, Rury R ^d   Zinman, Bernard ^e   Skyler, Jay S ^f   Green, Jennifer B ^g   Buse, John B ^h   Inzucchi, Silvio E ⁱ   Leiter, Lawrence A ^j   Raz, Itamar ^k   Rosenstock, Julio ^l   Riddle, Matthew C ^m  

^a AMERICAN DIABETES ASSOCIATION   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ YALE NEW HAVEN HOSPITAL   (United States)

^j ST MICHAEL'S HOSPITAL   (Canada)

^k HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^l UNIVERSITY OF TEXAS AT DALLAS   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALEGLITAZAR; CANAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLIMEPIRIDE; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSIDASE INHIBITOR; INSULIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ALL CAUSE MORTALITY; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL RESEARCH; DRUG EFFICACY; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LOW RISK POPULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT ADVOCACY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STUDY DESIGN; AGED; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOASSAY; CARDIOVASCULAR SYSTEM; COMPLICATION; FEMALE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 85038951494     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci17-0057     Document Type: Article

References (97)

1. U.S. Food, and Drug Administration. Guidance for industry: diabetes mellitusdevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [Internet]. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 31 October 2016
2. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the KellyWestAward Lecture 2008. Diabetes Care 2010; 33: 442-449
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction, and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471
4. Caveney E, Turner JR.White paper. A review of FDA guidance: understanding the FDA guidance on assessing cardiovascular risks for new antidiabetic therapies [Internet]. Available from http://www.quintiles.com/library/white-papers/newfda-guidance-on-antidiabetic-therapies. Accessed 31 October 2016
5. EuropeanMedicinesAgency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet], 2012. Available from http://www.ema .europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500129256.pdf. Accessed 3 November 2016
6. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee, and Investigators. Saxagliptin, and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
7. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
8. Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242
9. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes, and acute coronary syndrome. N Engl J Med 2015; 373: 2247-2257
10. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide, and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016; 375: 311-322
11. Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
12. Holman RR, Bethel MA, Mentz RJ, et al. EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228-1239
13. Zinman B, Wanner C, Lachin JM, et al. EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
14. Neal B, Perkovic V, Mahaffey KW, et al. CANVASProgramCollaborativeGroup. Canagliflozin, and cardiovascular, and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
15. Rawshani A, Rawshani A, Franzén S, et al. Mortality, and cardiovascular disease in type 1, and type 2 diabetes. N Engl J Med 2017; 376: 1407-1418
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment ofHigh Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
17. Nathan DM, Genuth S, Lachin J, et al. Diabetes Control, and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development, and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment, and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
19. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
20. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl JMed 2008; 358: 2545-2559
21. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control, and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
22. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control, and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139
23. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117
24. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes, and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772
25. Turnbull FM, Abraira C, Anderson RJ, et al. ControlGroup. Intensive glucose control andmacrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-2298
26. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control, and Complications Trial/Epidemiology of Diabetes Interventions, and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment, and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653
27. Orchard TJ, Nathan DM, Zinman B, et al. Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes, and long-term mortality. JAMA 2015; 313: 45-53
28. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes.NEngl JMed 2008; 359: 1577-1589
29. Hayward RA, Reaven PD, Wiitala WL, et al. VADT Investigators. Follow-up of glycemic control, and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197-2206
30. ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care 2016; 39: 701-708
31. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008-2017
32. John M, Gopalakrishnan Unnikrishnan A, Kalra S, Nair T. Cardiovascular outcome trials for anti-diabetes medication: a holy grail of drug development? Indian Heart J 2016; 68: 564-571
33. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death, and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294: 2581-2586
34. Drugs.com. Bristol-Myers Squibb, and Merck joint statement on FDA advisory committee vote on Pargluva (muraglitazar), an investigational oral treatment for type 2 diabetes [Internet]. Available from https://www.drugs.com/nda/pargluva-050909.html. Accessed 3 November 2016
35. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): amulticentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135
36. Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013; 166: 240-249.e1
37. U.S. Food, and Drug Administration. FDA drug safety communication: FDA requires removal of some prescribing, and dispensing restrictions for rosiglitazone-containing diabetes medicines [Internet]. Available from https://www.fda.gov/drugs/drugsafety/ucm376389.htm. Accessed 9 November 2017
38. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289
39. Kernan WN, Viscoli CM, Furie KL, et al. IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374: 1321-1331
40. Young LH, Viscoli CM, Curtis JP, et al. IRIS Investigators. Cardiac outcomes after ischemic stroke or TIA: effects of pioglitazone in patients with insulin resistance without diabetes. Circulation 2017; 135: 1882-1893
41. U.S. Food, and Drug Administration Center for Drug Evaluation, and Research. Application Number 204042Orig1s000: summary review [Internet]. Available from https://www .accessdata.fda.gov/drugsatfda-docs/nda/2013/204042Orig1s000SumR.pdf. Accessed 5 May 2017
42. Regier EE, Venkat MV, Close KL. More than seven years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications. Clin Diabetes 2016; 34: 173-180
43. Novo Nordisk. Novo Nordisk receives complete response letter in the US for Tresiba, and Ryzodeg [Internet]. Available from https://www .novonordisk.com/bin/getPDF.1676900.pdf. Accessed 4 November 2016
44. Boehringer Ingelheim. CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes. In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https://clinicaltrials.gov/show/NCT01243424. NLM Identifier: NCT01243424. Accessed 6 April 2017
45. Boehringer Ingelheim. Cardiovascular, and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus (CARMELINA). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library ofMedicine. Available from https://clinicaltrials.gov/show/NCT01897532. NLM Identifier: NCT01897532. Accessed 10 February 2017
46. Janssen Research, & Development. Evaluation of the effects of canagliflozin on renal, and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https://clinicaltrials.gov/show/NCT02065791. NLM Identifier: NCT02065791. Accessed 10 February 2017
47. AstraZeneca.Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI 58). In: Clinical-Trials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https://clinicaltrials.gov/show/NCT01730534. NLM Identifier: NCT01730534. Accessed 10 February 2017
48. Merck Sharp, & Dohme. Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease, the VERTIS CV study (MK-8835-004). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available fromhttps://clinicaltrials.gov/show/NCT01986881. NLM Identifier: NCT01986881. Accessed 14 February 2017
49. AstraZeneca. Study to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure (Dapa-HF). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https://clinicaltrials.gov/show/NCT03036124. NLM Identifier: NCT03036124. Accessed 6 April 2017
50. AstraZeneca. A study to evaluate the effect of dapagliflozin on renal outcomes, and cardiovascular mortality in patients with chronic kidney disease (Dapa-CKD). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https://clinicaltrials.gov/show/NCT03036150. NLM Identifier: NCT03036150. Accessed 4 April 2017
51. Boehringer Ingelheim. Empagliflozin outcome trial in patients with chronic heart failure with reduced ejection fraction (EMPERORReduced). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https://clinicaltrials.gov/show/NCT03057977. NLM Identifier: NCT03057977. Accessed 6 April 2017
52. Boehringer Ingelheim. Empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction (EMPERORPreserved). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine. Available from https://clinicaltrials.gov/show/NCT03057951. NLM Identifier: NCT03057951. Accessed 6 April 2017
53. Intarcia Therapeutics. Intarcia announces successful cardiovascular safety results in phase 3 FREEDOM-CVO trial for ITCA 650, an investigational therapy for type 2 diabetes: company also reports new$75million financing formanufacturing scale-up, and inventory build for anticipated global launch of ITCA 650 [Internet]. Available from https://www.intarcia.com/media/pressreleases/2016-may-6-cardiovascular-safety.html. Accessed 14 February 2017
54. Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Trial Investigators. Design, and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab 14 July 2017 [Epub ahead of print]. https://doi.org/10.1111/dom.13028
55. GlaxoSmithKline. Effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in subjects with type 2 diabetes mellitus. In: ClinicalTrials.gov [Internet]. Available from https://clinicaltrials.gov/show/NCT02465515. NLM Identifier: NCT02465515. Accessed 14 February 2017
56. Novo Nordisk A/S. A trial investigating the cardiovascular safety of oral semaglutide in subjects with type 2 diabetes (PIONEER 6). In: ClinicalTrials.gov [Internet]. Available fromhttps://clinicaltrials.gov/show/NCT02692716. NLM Identifier: NCT02692716. Accessed 29 June 2017
57. Marso SP, McGuire DK, Zinman B, et al. DEVOTE Study Group. Efficacy, and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017; 377: 723-732
58. Holman RR, Coleman RL, Chan JCN, et al. ACE Study Group. Effects of acarbose on cardiovascular, and diabetes outcomes in patients with coronary heart disease, and impaired glucose tolerance (ACE): a randomised, double-blind, placebocontrolled trial. Lancet Diabetes Endocrinol 2017; 5: 877-886
59. Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure, and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-2076
60. Wanner C, Inzucchi SE, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
61. Theodorakis MJ, Coleman RL, Feng H, et al. Baseline characteristics, and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. Am. Heart J. 1 September 2017 [Epub ahead of print]. https://doi.org/10/1016/j.ahj .2017.09.001
62. Gantz I, Chen M, Suryawanshi S, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2017; 16: 112
63. Merck.Merck provides update on filing plans for omarigliptin, an investigationalDPP-4 inhibitor for type 2 diabetes [Internet]. Available from http://www.mrknewsroom.com/news/companystatements/merck-provides-update-filing-plansomarigliptin-investigational-dpp-4-inhibi. Accessed 7 April 2017
64. U.S. Food, and Drug Administration. FDA drug safety communication: FDA adds warnings about heart failure risk to labels of type 2 diabetesmedicines containing saxagliptin, and alogliptin [Internet]. Available from http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm. Accessed 1 January 2017
65. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes, and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013; 10: 289-301
66. Neal B, Perkovic V, Matthews DR, et al. CANVAS-R Trial Collaborative Group. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVASR): a randomized, placebo-controlled trial. Diabetes Obes Metab 2017; 19: 387-393
67. Eli Lilly. Jardiance (empagliflozin) tablets to be studied in chronic kidney disease [Internet]. Available from https://investor.lilly.com/releasedetail. cfm?releaseid=1029854. Accessed 11 October 2017
68. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care 2016; 39: 1108-1114
69. Mudaliar S, Alloju S, Henry RR. Can shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016; 39: 1115-1122
70. Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ. Cardiovascular disease, and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care 2017; 40: 813-820
71. U.S. Food, and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adultswith type 2 diabetes [Internet]. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. Accessed 14 February 2017
72. American Diabetes Association. Pharmacologic approaches to glycemic control. Sec. 8. In Standards of Medical Care in Diabetesd2017. Diabetes Care 2017; 40(Suppl. 1): S64-S74
73. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013; 166: 217-223.e11
74. Janssen Pharmaceuticals. FDA briefing document: NDA 204042 Invokana (canagliflozin) tablets [Internet]. Endocrinologic, and Metabolic Drugs Advisory Committee Meeting. 10 January 2013. Available from https://wayback.archive-it .org/7993/20170405220010/https://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM334550.pdf. Accessed 10 October 2017
75. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Programcollaborative group. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS, and CANVAS-R trials. Diabetes Obes Metab 2017; 19: 926-935
76. Victoza liraglutide injection 1.2 mg/1.8 mg [prescribing information]. Plainsboro, NJ, Novo Nordisk, 2017
77. Novo Nordisk. Semaglutide receives positive 16-0 vote in favour of approval fromFDA Advisory Committee [Internet]. Available from https://www.novonordisk.com/bin/getPDF.2142854.pdf. Accessed 19 October 2017
78. Intarcia Therapeutics. Intarcia submits new drug application (NDA) to FDA for U.S. marketing approval of ITCA 650 in type 2 diabetes [Internet]. Available from https://www.intarcia.com/media/press-releases/2016-nov-21-nda-submission.html. Accessed 10 April 2017
79. Lincoff AM, Tardif J-C, Schwartz GG, et al. AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014; 311: 1515-1525
80. Erdmann E, Califf R, Gerstein HC, et al. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with type 2 diabetes mellitus or prediabetes. Am Heart J 2015; 170: 117-122
81. Vaccaro O, Masulli M, Nicolucci A, et al. Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017; 5: 887-897
82. Gerstein HC, Bosch J, Dagenais GR, et al. ORIGIN Trial Investigators. Basal insulin, and cardiovascular, and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328
83. ORIGIN Trial Investigators. Cardiovascular, and other outcomes postintervention with insulin glargine, and omega-3 fatty acids (ORIGINALE). Diabetes Care 2016; 39: 709-716
84. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes 2016; 40: 484-486
85. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2: 843-851
86. Fitchett D, Zinman B, Wanner C, et al. EMPAREG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 2016; 37: 1526-1534
87. Weidmann P, Ferrari P. Central role of sodium in hypertension in diabetic subjects. Diabetes Care 1991; 14: 220-232
88. Gerstein HC, Miller ME, Genuth S, et al. ACCORD Study Group. Long-termeffects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828
89. TheNNT Group. Quick summaries of evidencebased medicine [Internet]. Available from http://www.thennt.com. Accessed 5 February 2017
90. Jones WS, Roe MT, Antman EM, et al. The changing landscape of randomized clinical trials in cardiovascular disease. J Am Coll Cardiol 2016; 68: 1898-1907
91. Bethel MA, Holman R, Haffner SM, et al. Determining themost appropriate components for a composite clinical trial outcome. Am. Heart J 2008; 156: 633-640
92. Stolker JM, Spertus JA, Cohen DJ, et al. Rethinking composite end points in clinical trials: insights from patientsandtrialists. Circulation2014; 130: 1254-1261
93. Pocock SJ, Clayton TC, Stone GW. Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol 2015; 66: 2757-2766
94. Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail 2014; 2: 289-297
95. Rogers JK, Pocock SJ, McMurray JJ, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail 2014; 16: 33-40
96. Gallin EK, Bond E, Califf RM, et al. Forging stronger partnerships between academic health centers, and patient-driven organizations. Acad Med 2013; 88: 1220-1224
97. Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks, and benefits of glucose-loweringmedications.Am JMed 2010; 123: 374.e9-e18